



Curriculum Vitae

Personal information Edward Laane

Work experience

1. Employer: Tartu University
 - Start date: 091997
 - End date: 082001
 - Position: Resident of Hematology
 - Activities: Training in Hematology
 - Country: Estonia
2. Employer: Karolinska Institutet
 - Start date: 042002
 - End date: 092006
 - Position: PhD student
 - Activities: Research in experimental oncology and pathology
 - Country: Sweden
3. Employer: Tartu University
 - Start date: 092001
 - End date: 112011
 - Position: PhD student
 - Activities: Research in hematology
 - Country: Estonia
4. Employer: North Estonia Regional Hospital
 - Start date: 092006
 - End date: 122007
 - Position: Hematologist
 - Activities: Physician
 - Country: Estonia
5. Employer: North Estonia Regional Hospital
 - Start date: 012008
 - End date: 062010
 - Position: Head of Department of Hematology
 - Activities: Administrative
 - Country: Estonia
6. Employer: North Estonia Medical Center
 - Start date: 072010
 - End date: 122012
 - Position: Head of Center of Hematology
 - Activities: Administrative
 - Country: Estonia
7. Employer: Tartu University
 - Start date: 032008
 - End date: 012016
 - Position: Assistant
 - Activities: Teaching
 - Country: Estonia
8. Employer: North Estonia Regional Hospital
 - Start date: 012013
 - End date: 122017
 - Position: Senior Consultant Haematologist – lecturer
 - Activities: Physician and teaching
 - Country: Estonia
9. Employer: Dana_Farber Cancer Institute
 - Start date: 012015
 - End date: 122015
 - Position: Research Scholar
 - Activities: Genomic instability studies in multiple myeloma
 - Country: United States
10. Employer: Tartu University
 - Start date: 022016
 - End date:
 - Position: Associate professor of Hematology
 - Activities: Teaching, research and administrative
 - Country: Estonia
11. Employer: Kuressaare Hospital
 - Start date: 052018
 - End date:
 - Position: Member of the Board
 - Activities: Administrative and Physician, Head Doctor
 - Country: Estonia

Education and training

1. Subject: Tartu University
 - Start date: 091990

- End date: 061996
 - Qualification: Physician
 - Organisation:
 - Country: Estonia
2. Subject: Tartu University
- Start date: 091996
 - End date: 061997
 - Qualification: Internship
 - Organisation:
 - Country: Estonia

Additional information

Publications

1) Salek S, Ionova T, Oliva EN, Andreas M, Skoetz N, Kreuzberger N, Laane E. The Reporting, Use, and Validity of Patient-Reported Outcomes in Multiple Myeloma in Clinical Trials: A Systematic Literature Review. *Cancers (Basel)*. 2022 Dec 6;14(23):6007. doi: 10.3390/cancers14236007. 2) COVID_19 Host Genetics Initiative. A first update on mapping the human genetic architecture of COVID_19. *Nature*. 2022 Aug;608(7921):E1_E10. doi: 10.1038/s41586_022_04826_7. Epub 2022 Aug 3. 3) COVID_19 Host Genetics Initiative. Mapping the human genetic architecture of COVID_19. *Nature*. 2021 Dec;600(7889):472_477. doi: 10.1038/s41586_021_03767_x. Epub 2021 Jul 8. 4) Pikta M, Banys V, Szanto T, Joutsu-Korhonen L, Vaide I, Varik M, Lehtinen AE, Giangrande P, Laane E. Von Willebrand Factor Multimeric Assay in Acquired von Willebrand Disease Diagnosis: A Report of Experience from North Estonia Medical Centre. *J Lab Physicians*. 2021 Sep;13(3):195_201. doi: 10.1055/s_0041_1730818. Epub 2021 Jun 28. 5) Yu JK, Iorio A, Edginton AN; WAPPS co-investigators. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. *Res Pract Thromb Haemost*. 2019 May 20;3(3):528_541. doi: 10.1002/rth2.12204. eCollection 2019 Jul. Review. Erratum in: *Res Pract Thromb Haemost*. 2019 Sep 16;3(4):771. 6) Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Durán MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pečeliūnas V, Willenbacher W, Silva J, Louw V, Nemet D, Bórbényi Z, Abadi U, Pedersen RS, Černelc P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M; EMMOS Investigators. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. *Clin Lymphoma Myeloma Leuk*. 2018 Oct;18(10):e401_e419. doi: 10.1016/j.clml.2018.06.018. Epub 2018 Jun 25. 7) Tzoganis K, van Hennik P, Walsh J, De Graeff P, Folin A, Sjöberg J, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. *Oncologist*. 2018 May;23(5):631_636. doi: 10.1634/theoncologist.2017_0301. Epub 2017 Nov 30. Erratum in: *Oncologist*. 2018 Jul;23(7):870_870. 8) Tzoganis K, Camarero Jimenez J, Garcia I, Sancho-López A, Martin M, Moreau A, Demolis P, Salmonson T, Bergh J, Laane E, Ludwig H, Gisselbrecht C, Pignatti F. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. *Oncologist*. 2017 Nov;22(11):1339_1346. doi: 10.1634/theoncologist.2017_0184. Epub 2017 Sep 21. 9) D'Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastritis E, Laane E, Leblond V, Merlini G, Treon SP, Vos JM, Lunn MP. Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM_8 consensus panel. *Br J Haematol*. 2017 Mar;176(5):728_742. doi: 10.1111/bjh.14492. Epub 2017 Feb 15. 10) Berntorp E, Dargaud Y, Hart D, Lobet S, Mancuso ME, d'Oiron R, Perry D, Pollard D, van den Berg M, Blatný J, Chambost H, Doria AS, Holme PA, Kaczmarek R, Mantovani L, McLaughlin P, Nanayakkara L, Petrini P, Sannié T, Laane E, Maia R, Dettoraki A, Farrell A, Halimeh S, Raza S, Taylor S. The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany. *Eur J Haematol*. 2017 Jan;98 Suppl 85:1_15. doi: 10.1111/ejh.12828. 11) Hulegårdh E, Punab M, Holmberg E, Palk K, Laane E, Everaus H, Wennström L, Stockelberg D. Acute de novo Leukemia in Estonia and Western Sweden 1982_2006: Positive Trend in the Survival of Acute Leukemia over 25 Years. *Acta Haematol*. 2016;136(3):167_73. doi: 10.1159/000446525. 12) Gravanis I, Tzoganis K, van Hennik P, de Graeff P, Mueller-Berghaus J, Salmonson T, Gisselbrecht C, Laane E, Bergmann L, Pignatti F. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. *Oncologist*. 2016 Jan;21(1):102_9. doi: 10.1634/theoncologist.2015_0276. 13) Bron D, Ades L, Fulop T, Goede V, Stauder R; Elderly Task Force in Hematology EHA SWG. Aging and blood disorders: new perspectives, new challenges. *Haematologica*. 2015 Apr;100(4):415_7. doi: 10.3324/haematol.2015.126771. 14) Hanaizi Z, Flores B, Hemmings R, Camarero J, Sancho-Lopez A, Salmonson T, Gisselbrecht C, Laane E, Pignatti F. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. *Oncologist*. 2015 Mar;20(3):329_34. doi: 10.1634/theoncologist.2014_0073. Review. 15) Derolf AR, Laane E, Björklund E, Saft L, Björkholm M, Porwit A. Dendritic cells in bone marrow at diagnosis and after chemotherapy in adult patients with acute myeloid leukaemia. *Scand J Immunol*. 2014 Dec;80(6):424_31. doi: 10.1111/sji.12223. 16) Hanaizi Z, Unkrig C, Enzmann H, Camarero J, Sancho-Lopez A, Salmonson T, Gisselbrecht C, Laane E, Pignatti F. The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use. *Oncologist*. 2014 Apr;19(4):421_5. doi: 10.1634/theoncologist.2013_0294. Epub 2014 Mar 25. 17) Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, Steingrimsdottir H, Abildgaard N, Ahlberg L, Blimark C, Dahl IM, Forsberg K, Gedde-Dahl T, Gregersen H, Gruber A, Guldbrandsen N, Haukås E, Carlson K, Kvam AK, Nahi H, Lindås R, Andersen NF, Turesson I, Waage A, Westin J; Nordic Myeloma Study Group. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. *Blood*. 2013 Jun 6;121(23):4647_54. doi: 10.1182/blood_2012_11_464503. Epub 2013 Apr 24. 18) Péan E, Flores B, Hudson J, Sjöberg J, Dunder K, Salmonson T, Gisselbrecht C, Laane E, Pignatti F. The European Medicines Agency Review of Pixa-trone for the Treatment of Adult Patients With Multiply Relapsed or Refractory Aggressive Non-Hodgkin's B-Cell Lymphomas: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. *Oncologist*. 2013;18(5):625_33. doi: 10.1634/theoncologist.2013_0020. Epub 2013 Apr 24. 19) Punab M, Palk K, Varik M, Laane E, Everaus H, Holmberg E, Hulegårdh E, Wennström L, Safai-Kutti S, Stockelberg D, Kutti J. Sequential population-based studies over 25 years on the incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1982_2006: a survey of patients aged ≥65 years. *Med Oncol*. 2013 Mar;30(1):487. doi: 10.1007/s12032_013_0487_x. Epub 2013 Feb 9. 20) Kharaziha P, De Raeve H, Fristedt C, Li Q, Gruber A, Johnsson P, Kokaraki G, Panzar M, Laane E, Osterborg A, Zhivotovsky B, Jernberg-Wiklund H, Grandér D, Celsing F, Björkholm M, Vanderkerken K, Panaretakis T. Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the ST33MM mouse model. *Cancer Res*. 2012 Oct 15;72(20):5348_62. doi: 10.1158/0008_5472.CAN_12_0658. Epub 2012 Sep 4. 21) Buentke E, Nordström A, Lin H, Björklund AC, Laane E, Harada M, Lu L, Tegnebratt T, Stone-Elander S, Heyman M, Söderhäll S, Porwit A, Ostenson CG, Shoshan M, Tamm KP, Grandér D. Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells. *Blood Cancer J*. 2011 Jul;1(7):e31. doi: 10.1038/bcj.2011.27. Epub 2011 Jul 29. 22) Grandér D, Kharaziha P, Laane E, Pokrovskaja K, Panaretakis T. Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies. *Autophagy*. 2009 Nov;5(8):1198_200. Epub 2009 Nov 18. 23) Laane E, Tamm KP, Buentke E, Ito K, Kharaziha P, Oscarsson J, Corcoran M, Björklund AC, Hultenby K, Lundin J, Heyman M, Söderhäll S, Mazur J, Porwit A, Pandolfi PP, Zhivotovsky B, Panaretakis T, Grandér D. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. *Cell Death Differ*. 2009 Jul;16(7):1018_29. doi: 10.1038/cdd.2009.46. Epub 2009 Apr 24. Erratum in: *Cell Death Differ*. 2009 Jul;16(7):1071. Kharaziha, P [corrected to Kharaziha, P]. 24) Laane E, Panaretakis T, Pokrovskaja K, Buentke E, Corcoran M, Söderhäll S, Heyman M, Mazur J, Zhivotovsky B, Porwit A, Grandér D. Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members. *Haematologica*. 2007 Nov;92(11):1460_9. 25) Laane E, Björklund E, Mazur J, Lönnholm G, Söderhäll S, Porwit A. Dendritic cell regeneration in the bone marrow of children treated for acute lymphoblastic leukaemia. *Scand J Immunol*. 2007 Nov;66(5):572_83. Epub 2007 Sep

24. 26) Laane E, Derolf AR, Björklund E, Mazur J, Everaus H, Söderhäll S, Björkholm M, Porwit_MacDonald A. The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post_remission chemotherapy. *Haematologica*. 2006 Jun;91(6):833_6. 27) Panaretakis T, Laane E, Pokrovskaja K, Björklund AC, Moustakas A, Zhivotovsky B, Heyman M, Shoshan MC, Grandér D. Doxorubicin requires the sequential activation of caspase_2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. *Mol Biol Cell*. 2005 Aug;16(8):3821_31. Epub 2005 May 25. 28) Laane E, Tani E, Björklund E, Elmberger G, Everaus H, Skoog L, Porwit_MacDonald A. Flow cytometric immunophenotyping including Bcl_2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non_Hodgkin's lymphoma. *Cytometry B Clin Cytom*. 2005 Mar;64(1):34_42. 29) Laane E, Nanjappa P, Kumar S, Magrangeas F, Minvielle S, Everaus H, Kenneth C Anderson KC, Avet-Loiseau H, Shamma MA, PhD and Munshi NC. XRCC5 Plays an Important Role in Homologous Recombination, Genome Stability and Survival of Myeloma Cells. Poster presentation in 57th ASH Annual Meeting and Exposition, December 5_8, 2015, Orlando, FL, USA.

Projects World Federation of Hemophilia, Hemophilia Treatment Centre Twinning Project, 2014_2017, Tallinn (Estonia) _ Helsinki (Finland)

Memberships Past President of the Estonian Society of Hematology 2010_2013 Member of European Hematology Association European Hematology Association Scientific Working on Group Quality of Life and Symptoms, Chair Member of the Japanese Society of Hematology Member of Nordic Myeloma Study Group Member of Nordic Chronic Myeloid Leukemia Study Group Member of Nordic Lymphoma Study Group

Other Relevant Information